Previous 10 | Next 10 |
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 PR Newswire – $148.0 Million (86%) of Existing Convertible Notes due in 2025 to be Exchanged for $111.0 Millio...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
2024-05-07 11:43:08 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript Karyopharm Therapeutics Inc. 2023 Q4 - Results - Earnings Call Presentation ...
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 PR Newswire -- Conference Call Scheduled for Wednesday, May 8, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , May 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPT...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-04-30 14:28:23 ET Summary Karyopharm Therapeutics Inc.'s selinexor is being featured in 7 presentations at ASCO. The company is also exploring selinexor's potential role in myelofibrosis, with two key trials planned. Karyopharm Therapeutics' cash position is a challenge, ...
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting PR Newswire Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates" ...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences PR Newswire NEWTON, Mass. , March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company ...
2024-02-29 18:15:15 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q4 2023 Earnings Call Feb 29, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q4 2023 Earnings C...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...